Sutro Biopharma (STRO) Cash from Operations (2017 - 2025)

Sutro Biopharma has disclosed Cash from Operations across 9 years of filings, most recently posting 26435000.0 for Q4 2025.

• Cash from Operations for Q4 2025 came in at 26435000.0, up 63.15% year-over-year; the trailing twelve-month figure through Dec 2025 was 177231000.0 (up 7.47% YoY), and the FY2025 annual result was 177231000.0, up 7.47% from the prior year.
• Cash from Operations came in at 26435000.0 for Q4 2025 at Sutro Biopharma, up from 38189000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 65854000.0 in Q3 2022 to a low of 71738000.0 in Q4 2024.
• The 5-year median for Cash from Operations is 30812500.0 (2021), against an average of 27925850.0.
• Across the five-year window, Cash from Operations jumped 369.83% in 2022 and slumped 879.13% in 2023, its largest moves.
• Sutro Biopharma's Cash from Operations stood at 21580000.0 in 2021, then slipped by 10.58% to 23864000.0 in 2022, then jumped by 158.97% to 14072000.0 in 2023, then plunged by 609.79% to 71738000.0 in 2024, then soared by 63.15% to 26435000.0 in 2025.
• The last three Cash from Operations figures came in at 26435000.0 (Q4 2025), 38189000.0 (Q3 2025), and 44724000.0 (Q2 2025), per Business Quant data.